25M+ adverse event reports, 577K clinical trials, Part D formulary coverage, prescribing intelligence, and Open Payments data. The dimensions that IQVIA charges $100K+ for, plus drug safety, device recalls, and provider intelligence, all at from $199/month.
IQVIA
Claims data, prescribing analytics, formulary, clinical trials
Citeline / Pharma Intelligence
Clinical trial intelligence, drug pipeline, investigator data
GlobalData
Drug intelligence, trials, pricing, patents, competitive landscape
Oracle Argus / Veeva Vault
Pharmacovigilance case management, adverse event processing
IPD Analytics / MMIT
Formulary insights, payer coverage, brand impact forecasts
Total per year
$405K–$2.4M+(dimensions we cover)Ask in plain English. Follow up to drill deeper. One conversation replaces multiple vendor dashboards.
FAERS Adverse Event Search (25M+ reports)
Search the full FDA Adverse Event Reporting System, 25M+ reports with drug names, reactions, outcomes, demographics. Find safety signals, compare drugs, track trends by quarter. No IQVIA or Oracle contract needed.
You ask
“Show me all serious adverse events for Ozempic in the past 2 years”
Then follow up
“Compare the adverse event profile of Ozempic vs Mounjaro. Which has more cardiac events?”
“What’s the trend in Ozempic reports by quarter? Is the safety signal growing or stabilizing?”
Clinical Trials Database (577K trials)
Search 577K clinical trials by drug, condition, phase, sponsor, or investigator. Track competitive pipelines, find active trials at specific facilities, monitor enrollment status.
You ask
“Find all Phase 3 trials for GLP-1 agonists. Who’s running them and where?”
Then follow up
“Which sites are enrolling fastest? Show me the top 10 by enrollment rate.”
“Are any of these trials at hospitals we’re considering for acquisition?”
Part D Formulary Coverage (1.12M mappings)
1.12M drug-plan-tier mappings with prior authorization, step therapy, and quantity limits. See which plans cover a drug, at what tier, and with what restrictions. Competitive formulary positioning.
You ask
“Which Medicare Part D plans cover Jardiance? What tier and restrictions?”
Then follow up
“Compare Jardiance vs Farxiga formulary coverage. Which has better access across plans?”
“How many plans require prior auth for Jardiance? How does that compare to 2 years ago?”
Prescribing Intelligence
Medicare Part D prescribing data by provider, drug, and geography. See who prescribes what, how much, and how they compare to peers. Identify key opinion leaders by prescribing volume.
You ask
“Who are the top 20 Ozempic prescribers in Texas?”
Then follow up
“For the top prescriber, what else do they prescribe? What’s their full Part D profile?”
“Which specialties prescribe the most GLP-1 agonists? Endocrinology vs primary care?”
Medicaid Drug Utilization (9.3M rows)
Medicaid drug utilization data across 50 states, drug spend, units reimbursed, and utilization by drug, state, and year. Compare Medicare vs Medicaid drug spend patterns. Identify state-by-state access gaps. NADAC drug acquisition costs (1.6M rows) for net pricing benchmarks.
You ask
“Compare Medicaid vs Medicare utilization for GLP-1 drugs across states”
Then follow up
“Which states have the highest Medicaid spend on diabetes medications? How does that compare to Medicare?”
“Show NADAC acquisition costs for semaglutide vs tirzepatide. What’s the net cost difference?”
Open Payments (Industry Payments)
Every payment from pharma/device companies to physicians, by company, product, amount, and nature. Identify KOLs, speaker bureau members, and consulting relationships.
You ask
“Show me all payments from Novo Nordisk to physicians in 2023. Who got the most?”
Then follow up
“Cross-reference their top-paid physicians with their Ozempic prescribing volume. Is there correlation?”
“Which physicians received payments for speaking engagements vs consulting vs research?”
Drug Lookup & Safety Signals
Search any drug by name, adverse events, recalls, enforcement actions, label changes. Combine FAERS data with FDA enforcement to build a complete safety profile.
You ask
“Pull the full safety profile for this drug, adverse events, recalls, warnings”
Then follow up
“Are there any FDA enforcement actions or recalls for this drug in the past year?”
“Compare the safety signal for this drug vs the 3 closest competitors.”
Device Intelligence
44K+ device recalls, 510(k) and PMA approvals. Track competitive device landscape, monitor recalls, and identify surgeon procedure volumes for device targeting.
You ask
“Show me all Class I recalls for cardiac devices in the past 3 years”
Then follow up
“Which hospitals use the most of this device? Show me surgeon volumes by facility.”
Provider & Facility Intelligence
2.6M providers linked to 273K facilities. Identify high-volume prescribers, find investigators for trial sites, and map the competitive landscape by specialty and geography.
You ask
“Find all oncologists within 50 miles who prescribe this drug and participate in clinical trials”
Then follow up
“Which of these oncologists are also receiving industry payments? From which companies?”
Not clean, SaaS-y queries. These are the messy, multi-domain questions a pharma team actually asks on Monday morning, each one normally means IQVIA plus Citeline plus a safety vendor plus a KOL consultant.
“Pull all serious adverse events for our drug in the past quarter. Compare to the same period last year, is the signal growing, and is it concentrated in specific prescriber cohorts?”
“Cross-reference our top 50 KOLs’ prescribing data with their industry payments, recent trial participation, and any state board discipline. Which ones are risky to put on the next advisory board?”
“Find the top 50 prescribers of our competitor’s drug in Florida. What’s their prescribing profile, who’s paying them, and which ones are already in our Speaker Bureau pipeline?”
“Which Medicare Part D plans dropped coverage of our drug this year? Where did they move it on tier, and what’s the Medicaid picture in those same states?”
“Compare the adverse event profile of our drug vs. the 2 closest competitors. Which specific reactions are we higher on, and has any of them triggered MDL formation yet?”
“Show me all Phase 3 trials in our therapeutic area. Which competitors are furthest along, where are their trial sites, and who are the PIs we’d need to recruit if we wanted to compete?”
Medistill vs IQVIA
IQVIA owns proprietary claims. We cover the dimensions they charge $100K+ for, plus safety and compliance they don't.
See full comparison →Medistill vs Citeline
Citeline leads in trial intelligence. We add FAERS safety data, prescribing analytics, formulary coverage, and provider intelligence.
See full comparison →Medistill replaces:
We don't replace:
Medistill covers the data and intelligence layer. It complements proprietary data platforms, not replaces them.
Pricing
Pro $199 / 500 credits · Business $499 / 1,500 credits · Unlimited $999 ($9,990/yr) · Team from $599/seat
Full access to all 2,000+ datasets. No per-query fees. 1 credit per entity processed.
No credit card required. Expires in 15 days.